Hear from a Cytovance expert on how perfusion is benefiting from a wave of technological advances that are making the approach more practical and economically attractive for commercial-scale manufacturing.
Perfusion Technologies Gain Momentum in Biomanufacturing Read More »
Anixa Biosciences has selected Cytovance Biologics for Phase 2 Manufacturing of Breast Cancer Vaccine.
Building in Success: Integrating QbD Principles in Biologics Formulation Development Read More »
2026 is shaping up to be a year of steady progress for biopharmaceutical innovators. While development activity remains strong, sponsors are operating in a challenging environment characterized by increasingly complex modalities, lean resourcing, regulatory uncertainty, and heightened emphasis on supply chain resilience, pushing sponsors to rethink how they develop and manufacture their assets. Several key
Biomanufacturing Trends Shaping 2026 Read More »
While biopharma at large faces unprecedented pressure to innovate quickly and stay competitive, small biotech organizations are particularly impacted by compressed timelines, volatile funding, and evolving regulatory demands. CDMOs play a vital role in supporting biotech sponsors through these challenges with access to expert guidance and established development and manufacturing infrastructure. Leaders from both sides
The Clinical Translation from Bench to Bedside Bringing new and innovative therapeutics to patients is a fundamental purpose of translational science. This “bench-to-beside” process is centered around harnessing knowledge gained by basic research on the bench and reducing it to, eventually, a therapeutic practice bedside. Early drug developers constantly walk a balance between getting the
Regulatory Considerations for First-Time Drug Developers Read More »
Like most industries, the ever-evolving biopharmaceutical landscape often experiences its ebbs and flows, with emerging biotechnology companies feeling the direst of consequences. The COVID-19 pandemic marked a surge in investor enthusiasm in the biotech sector, fueled by overnight demand for innovative solutions to combat the virus. This period of heightened interest created a speculative “bubble”
Beyond Conventional: How Cytovance’s CDMO Model is Empowering Emerging Biotechs Read More »
Discover the role of Artificial Intelligence in revolutionizing biologics manufacturing and learn how Cytovance and partners at the University of Oklahoma are contributing to setting the new standard. Artificial Intelligence (AI) in Biomanufacturing At its core, AI involves the development of sophisticated algorithms and computational systems that can analyze vast sets of data, identify patterns
Advancing Biomanufacturing Excellence Through Artificial Intelligence Read More »
An efficient microbial strain development strategy stands as the cornerstone of expediting product development timelines and enhancing the overall product development process.
Microbial Strain Development Strategy to Enhance Product Development Read More »
Harnessing the incredible power of microorganisms to produce a wide array of valuable compounds is as old as recorded civilization and continues to be a testament to human ingenuity. Within this practice, microbial biomanufacturing has long represented a cutting-edge frontier in industrial processes with a rich history that serves as a foundation for the ongoing
A Brief History of Microbial Biomanufacturing: Where We’ve Been and Where We Are Going Read More »
One of the most critical points in a drug’s journey to patients is the successful scaling up from R&D to manufacturing. Having a seamless scale up process is essential for not only ensuring safety but also for maximizing the potential success of new drugs when they get to market. Though not a simple process, scale
5 Tips for Successfully Scaling from R&D to Manufacturing Read More »
